Buprenorphine Treatment from Your Own Doctor: Private, Office-Based, and Individualized

I have been prescribing buprenorphine for more than fifteen years, for opioid use disorders and for chronic pain. In that time it has gone from a medication most physicians could not legally prescribe to one of the most important tools in American medicine. The molecule has not changed. Nearly everything around it has: the law, the street drug supply, the protocols, and the kind of patient who walks into my office asking about it.

What buprenorphine actually does

Buprenorphine is a partial agonist at the mu opioid receptor. It binds tightly, activates the receptor partially, and stays put. In practice this means it relieves withdrawal and craving without producing the high-and-crash cycle of full agonists, and its ceiling effect on respiratory depression gives it a meaningfully wider safety margin than the opioids it replaces.

When the dose is right, the clinical effect is not intoxication. It is normalcy. Patients often describe being able to think about something other than opioids for the first time in years. That mental space is where recovery work actually happens.

One distinction matters here. Physical dependence is your body adapting to a medication, and it happens with blood pressure drugs and antidepressants too. Addiction is a pattern of compulsive use despite harm. Buprenorphine produces the first while treating the second, and confusing the two has kept too many people from care that works.

The end of the x-waiver

For two decades, federal law required a special waiver, known as the x-waiver, before a physician could prescribe buprenorphine for opioid use disorder. Congress eliminated that requirement at the end of 2022, and SAMHSA and the DEA implemented the change. Any clinician with a standard DEA registration can now prescribe it.

The years since have brought an explosion of new research, methods, and practice guidance. Programs like California Bridge built low-threshold pathways so treatment can start the day someone asks for it. Practice guides now cover techniques that barely existed a decade ago, such as buprenorphine cross-titration. Curated libraries like Dr. Kornfeld's resource collection track a literature that grows monthly.

More prescribers and better guidance are good for the country. They do not make every prescriber's care equivalent. Buprenorphine rewards experience: in patient selection, in dosing judgment, in knowing when the textbook answer is wrong for the person in front of you.

The fentanyl era changed the playbook

The shift from heroin and pills to high-potency synthetic opioids rewrote induction practice. Fentanyl lingers in the body, and the traditional approach of waiting for withdrawal before starting buprenorphine became harder to tolerate and riskier to time, since starting too early can precipitate the very withdrawal it is meant to prevent. Much of the recent innovation, including low-dose initiation and cross-titration approaches, exists precisely to solve this problem.

The guidelines keep improving, and we follow them closely. But a protocol is a starting point, not a destination. In reality, our uses of buprenorphine are more individualized than most protocols can capture, because the patients themselves are more individual than any protocol can capture.

Individualized beyond protocol

Fifteen years of using one medication teaches you its personality. Buprenorphine interacts with sleep, with mood, with pain, with the demands of a career and a family. The dose that quiets craving may need adjusting when chronic pain is part of the picture. The schedule that works for one person's physiology fails another's. Some patients do best with a brief stabilization and a slow taper; others do best on maintenance for years, and the evidence supports both paths when they are chosen deliberately.

Many of the people we treat are high-functioning professionals. High-functioning does not mean low-suffering. It usually means someone has been carrying a serious medical problem alone, quietly, at real cost, because the visible options for treatment felt incompatible with their work and their privacy. If I simply told such patients what they must do, on a schedule built for someone else, they would leave. Meeting people where they are is not a slogan in addiction medicine. It is the treatment.

We also use buprenorphine for chronic pain, where certain formulations are FDA-approved for that purpose and others are used off-label when the clinical picture justifies it. We are explicit with patients about which is which.

What treatment looks like in our practice

Every patient establishes care in person at our San Francisco office. That is true for every condition we treat, and it matters doubly for controlled substances, where careful initial evaluation is both good medicine and what the law expects. Once care is established, we can often use a hybrid approach for convenience, with some visits conducted remotely when that is appropriate for the clinical situation.

Visits are unhurried. We look at the whole picture: pain, sleep, mood, medications, work, family. We coordinate with therapists and psychiatrists when that helps, and we handle sensitive information the way a small, physician-owned practice can: carefully, personally, and with as few people involved as possible.

We do not promise outcomes. What we promise is attention, experience, and a plan built around you rather than around a protocol.

Common questions

Can any doctor prescribe buprenorphine now?

Legally, yes: since the x-waiver ended, any clinician with a standard DEA registration can prescribe buprenorphine for opioid use disorder. Practically, experience still matters a great deal, especially in the fentanyl era, where induction and dosing decisions have become more nuanced.

Do I have to go to a clinic every day?

No. Buprenorphine is office-based treatment. Federal rules generally reserve daily observed dosing for methadone, which is dispensed through specialized opioid treatment programs. Buprenorphine prescriptions are filled at an ordinary pharmacy, and visit frequency is tailored to where you are in treatment.

Is buprenorphine just trading one addiction for another?

No. Physical dependence on a prescribed, stable, monitored medication is a different phenomenon from addiction, which involves compulsive use despite harm. Long-term buprenorphine maintenance is a legitimate, evidence-supported path, and so is an eventual slow taper. Which one fits you is a decision we make together, revisited over time.

How discreet is treatment, really?

We are a small, physician-owned practice, and we control how your information is handled internally. We are candid with every patient about what we control and what any prescription inherently involves, and we are happy to walk through exactly how your information is handled before you commit to anything.

Do you offer buprenorphine treatment by telemedicine?

We do not provide telemedicine-only care for any condition. Patients establish care in person in San Francisco. After that, we can often use a hybrid approach for convenience, when it is appropriate for the clinical situation.

Talking with us

If you or someone you care about is weighing buprenorphine treatment, a conversation costs nothing and commits you to nothing. Contact Us Securely and we will follow up discreetly.

This article is for educational purposes only and does not constitute medical advice. Consult your physician before making changes to your health regimen.